MEG8：An Indispensable Long Non-coding RNA in Multiple Cancers

As a member of long non-coding RNAs (lncRNAs), maternally expressed gene 8 (MEG8) has been found involving in the progression of a variety of cancers and playing a regulatory role. Therefore, MEG8 may turn into a new therapeutic target for cancer in the future. The purpose of this review is to illus...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design
Main Authors Du, Zhuoying, Tan, Fangshun, Chen, Jinlan, Wang, Bei, Liu, Yuling, Zhao, Fangnan, Wu, Yinxin, Yuan, Chengfu
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2022
Subjects
molecular mechanism
therapy
therapeutic target
tumorigenesis
biomarker
MEG8
Long non-coding RNA
Online AccessGet more information

Cover

More Information
Summary:As a member of long non-coding RNAs (lncRNAs), maternally expressed gene 8 (MEG8) has been found involving in the progression of a variety of cancers and playing a regulatory role. Therefore, MEG8 may turn into a new therapeutic target for cancer in the future. The purpose of this review is to illustrate the molecular mechanism and physiological function of MEG8 in various cancers. We retrieved and analyzed related articles about MEG8, lncRNAs and cancers, and then summarize the pathophysiological mechanisms of MEG8 in cancer development. LncRNA MEG8 participates in various cancers progression, thus influencing the proliferation, migration, and invasion of cancers. However, the expression of MEG8 is abnormally upregulated in non-small cell lung cancer (NSCLC), pancreatic cancer (PC), liver cancer (HCC), pituitary adenoma (PA) and hemangioma (HA), and inhibited in colorectal cancer (CRC), ovarian cancer (OC) and giant cell tumor (GCT), suggesting its clinical value in cancer therapy. LncRNA MEG8 is expected to be a new therapeutic target or biomarker for a wide range of cancers in the future.
ISSN:1873-4286
DOI:10.2174/1381612828666220516090245